Citigroup Raises Integra LifeSciences (NASDAQ:IART) Price Target to $22.00

Integra LifeSciences (NASDAQ:IART) had its target price boosted by Citigroup from $16.00 to $22.00 in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a sell rating on the life sciences company’s stock.

Other analysts also recently issued research reports about the stock. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America reduced their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Morgan Stanley raised their target price on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus price target of $27.25.

Integra LifeSciences Stock Up 3.3 %

IART stock opened at $24.91 on Tuesday. The business has a 50-day simple moving average of $18.68 and a 200 day simple moving average of $24.41. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42. The company has a market cap of $1.93 billion, a PE ratio of 85.90, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the business posted $0.76 EPS. The business’s revenue was down .4% compared to the same quarter last year. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its stake in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in Integra LifeSciences during the third quarter worth $73,000. Canada Pension Plan Investment Board purchased a new stake in Integra LifeSciences in the 2nd quarter valued at $114,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Integra LifeSciences by 58.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.